CORONA Remedies enterprise value

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026
13,459—
1.81.8
143143
13,600—
141141
₹2,223.66—
890890
16.1%16.1%
0.01×—
9.19×—
42.93×—
49.53×—
245.75×—
Reference items — trailing FY values
1,4791,403
317293
275256
—229
55.355.3
—54.1
—174
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CORONA₹2,200.60

CORONA Remedies Ltd.

· Pharma & Health
₹ CrorePeersERISMANKINDAPLLTDALIVUSAKUMSAGARWALEYEHCGADVENZYMESMcap ₹13,459 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization—13,458.9
- Cash, Equiv & ST Investments1.81.8
+ Total Debt142.9142.9
Enterprise Value—13,599.9
Net Debt (memo)141.0141.0
EV per Share—2,223.66
Total Capital889.7889.7
Total Debt/Total Capital16.0616.06
Total Debt/EV—0.01
EV/Sales—9.19
EV/EBITDA—42.93
EV/EBIT—49.53
EV/Free Cash Flow—245.75
Reference Items — Trailing FY Values
Sales1,403.21,479.1
EBITDA293.4316.8
EBIT255.6274.6
Operating Cash Flow229.5—
Free Cash Flow55.355.3
FCFF (free cash flow to the firm)54.1—
Capital Expenditure174.1—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.